Loading the records…
Loading the records…
HR3906 (Medical Research for Our Troops Act) would restore $1.181B in military medical research funding, but the bill has been stalled in the House Appropriations Committee since June 2025 with zero legislative movement. Real market data shows healthcare stocks declining 3-8% over 30 days due to broader sector headwinds, not this bill. No actionable trade signal exists.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Zero market implications at current legislative stage. ($26.84), ($111.31), and ($316.60) are declining on unrelated healthcare sector pressure. Retail investors should ignore this bill as a trading catalyst. Any future movement would require the bill to advance out of committee and attract Republican support — track the House Appropriations Committee markup calendar, not stock prices.
Rep. Carson (D-IN) introduced HR3906 on June 11, 2025, to restore $1.181B to the Defense Health Agency's research, development, test, and evaluation budget — specifically the Congressionally Directed Medical Research Programs (CDMRP). The bill targets a funding cut in the Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L. 119-4), reverting it to FY2024 levels. Since introduction, the bill has collected 48 cosponsors (all Democrats) and was referred to the House Committee on Appropriations — where it has remained for nearly 11 months without a hearing, markup, or vote.
The money trail is critical here: HR3906 is an authorization bill that would amend the existing appropriations act to restore spending levels. However, it does not directly appropriate new money — it authorizes the Secretary of Defense to obligate funds consistent with FY2024 levels. Actual disbursement requires the appropriations committee to include this language in a future spending bill. Given the bill's early-stage status and lack of committee action, there is effectively zero probability of near-term enactment.
Structural winners from this bill would be biopharma and medical device companies that participate in CDMRP's peer-reviewed grant programs — typically large pharma (, ), medical device manufacturers, and academic medical centers. However, no companies are named in the bill text, and CDMRP grants are competitive, not guaranteed. The defense healthcare sector (military treatment facilities, research labs) would be the direct beneficiary, but the stalled legislative path means ZERO current impact on revenue or earnings guidance.
Real market data confirms no bill-related impact: at $26.84 (-4.45% 30-day), at $111.31 (-7.47% 30-day), and at $316.60 (-3.65% 30-day) are all declining on broad healthcare sector weakness — likely tied to drug pricing policy uncertainty, patent cliff concerns, or macro rotation — not a stalled research funding bill no investor is watching.
Timeline: The bill requires (1) House Appropriations Committee markup and report, (2) House floor vote, (3) Senate companion bill and passage, (4) conference committee, and (5) presidential signature. Given zero actions in 11 months and a Democratic sponsor in a Republican-controlled House (119th Congress, Republican majority), the path to enactment is exceptionally narrow. No meaningful legislative catalysts expected before the 2028 elections.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
Matched on shared policy language across AI analyses, with ticker & timing weight
MACRO OVERRIDE: West Bank Displacement
MACRO OVERRIDE: Strait of Hormuz Tensions
MACRO OVERRIDE: Hormuz Tanker Attack
MERCK SHARP & DOHME LLC: $2.0B Department of Health and Human Services Contract Vehicle
MACRO OVERRIDE: UK-China AI Cyber Conflict
Raytheon Co.: $2.6B Department of Defense Contract
Fluor Marine Propulsion LLC: $2.4B Department of Defense Contract
KestrelX LLC, * Driggs, Idaho (FA4890-27-D-0003); A2G International LLC, * Melbourne, Florida (FA4890-27-D-0002); and Fleet Adversary Support and Training LLC, * St. Augustine, Florida (FA4890-27-D-0001): $5.4B Department of Defense Contract
Executive orders & memoranda affecting the same sectors or companies
The President invokes Section 232 of the Trade Expansion Act to declare that imports of robotics, industrial machinery, and their components threaten national security, and directs the Secretary of Commerce and USTR to negotiate agreements with trading partners to adjust these imports, potentially leading to tariffs or quotas within 180 days.
This proclamation initiates negotiations to adjust imports of wind turbines and their components under Section 232, citing national security concerns including cybersecurity vulnerabilities, radar interference, and grid reliability. It does not immediately impose tariffs but sets the stage for potential trade restrictions, and notes that certain wind turbine components made of aluminum, steel, or copper are already subject to existing tariffs.
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →